Panorama: The Menopause Industry Uncovered, Βι¶ΉΤΌΕΔ One, 30 September 2024

Complaint

A viewer complained the programme was guilty of scaremongering about the risks from high levels of hormone replacement therapy. Β The ECU considered whether it met the standards for accuracy, and in particular for the portrayal of risk, set out in the Βι¶ΉΤΌΕΔ Editorial Guidelines.


Outcome

From the descriptions in the programme it was apparent that the risk to health from over-prescription was genuine in many cases and a matter for concern to the British Menopause Society, which is the specialist authority for menopause and post- reproductive health in the UK. Β In such circumstances, the ECU did not believe the programme was being unduly alarming in the way it described the problem.

Not Upheld